论文部分内容阅读
胃肠道间质瘤(gastrointestinal stromal tumor,GIST)是消化系统最常见的间叶组织源性肿瘤。近年来随着影像学、组织病理学、免疫组织化学以及分子生物学等相关学科的发展,其发病机制逐渐被人们所探知,发现GIST起源于消化道间质细胞Cajal细胞,原癌基因c-kit突变或PDGFRA突变与其发病密切相关,以CD117和CD34等为代表的免疫组织化学染色在其诊断中具有重要的决定性作用。目前手术完整切除仍为其首选治疗,以甲磺酸伊马替尼为代表的分子靶向药物的出现及新辅助治疗的应用成为GIST治疗上的一次巨大飞跃,让GIST患者看到了另一个春天。本文就GIST目前的认识和诊治进展作一综述。
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the digestive system. In recent years, with the development of imaging, histopathology, immunohistochemistry and molecular biology and other related disciplines, its pathogenesis has been gradually discovered, and found that GIST originated in the gastrointestinal stromal cells Cajal cells, proto-oncogene c- kit mutation or PDGFRA mutation is closely related to its pathogenesis. Immunohistochemical staining such as CD117 and CD34 plays an important and decisive role in its diagnosis. The current complete surgical resection is still its preferred treatment, the emergence of molecular targeted drugs represented by imatinib mesylate and the application of neoadjuvant therapy become a huge leap in the treatment of GIST, so GIST patients saw another spring . This article summarizes the current understanding and diagnosis and treatment progress of GIST.